Respiratory Muscle Strength and Aerobic Capacity in Scleroderma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Scleroderma Group, Healthy group.
- Who it may be relevant to
- Registry conditions: Scleroderma. Basic parameters: 18 years — 65 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Investigation of Respiratory Muscle Strength and Aerobic Capacity in Patients With Scleroderma
Overview
Primary aim of this study was to compare respiratory muscle strength, aerobic capacity, dyspnea, pulmonary function tests and fatigue values with healthy controls. The secondary aim was to evaluate the relationship between respiratory muscle strength and other parameters in these patients and to examine the factors that may affect respiratory muscle strength. Respiratory muscle strength, aerobic capacity, respiratory function tests and fatigue will be evaluated
Detailed description
Scleroderma is a systemic connective tissue disease characterized by progressive thickening of the skin, the etiology of which has not been fully elucidated, in which microvascular damage, immune activation and fibrosis play a role. Primary aim of this study was to compare respiratory muscle strength, aerobic capacity, dyspnea, pulmonary function tests and fatigue values with healthy controls. The secondary aim was to evaluate the relationship between respiratory muscle strength and other parameters in these patients and to examine the factors that may affect respiratory muscle strength. The study will include 15 patients and 15 healthy individuals of the same age and gender. Respiratory muscle strength, aerobic capacity, respiratory function tests and fatigue will be evaluated
Interventions
- Other Scleroderma Group
Scleroderma patients will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue. - Other Healthy group
Healthy people will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
Primary outcome measures
- Respiratory muscle strength assessment [Time frame: 5 minutes]
Secondary outcome measures (3)
- Aerobic capacity assessment [Time frame: 10 minutes]
- Fatigue assessment [Time frame: 2 minutes]
- Pulmonary function test [Time frame: 5 minutes]
Eligibility criteria
Inclusion criteria
- Being diagnosed with Ssk according to ACR/EULAR criteria
- Stable medical treatment for 3 months
Exclusion criteria
- Having a regular exercise habit (doing regular exercise at least once a week for the last 3 months)
- Comorbidity with another chronic disease that may affect aerobic capacity or respiratory muscle strength
- Having concomitant acute respiratory diseases
- Having a smoking habit
- History of orthopedic or neurologic disease in the lower extremities that may prevent cycling
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Other
Study locations
Turkey (Türkiye) · 1 center
- Songul Baglan Yentur — Elâzığ
Identifiers
NCT: NCT06554132 · 2024/10-02